<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; BioDelivery Sciences International Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/biodelivery-sciences-international-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(CEPH) Cephalon Second Quarter 2010 Earnings Report Beats The Street</title>
		<link>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093</link>
		<comments>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:55:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45093</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) delivered another strong quarter with second quarter earnings coming in at $2.05 per share, six cents above the Zacks Consensus Estimate and well above the year-ago earnings of $1.44 per share. We note that the Zacks Consensus Estimate had been revised recently following Cephalon’s announcement that it expects to deliver second quarter earnings above its previously issued guidance. Strong revenues helped the company post impressive results. Revenue increased 32.7% to $726.9 million, exceeding the Zacks Consensus Estimate by almost $19 million. The Mepha acquisition contributed $90 million to second-quarter revenue. The Quarter in Detail Second-quarter revenue consisted of $712.4 million in product sales (up 32.2%) and $14.5 million in other revenue. Revenue was driven by contributions from the central nervous system (CNS) and oncology franchises, which posted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/ceph-cephalon-second-quarter-2010-earnings-report-beats-the-street/45093/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon&#8217;s Quarterly Earnings Report Beats &#8211; Updates Guidance</title>
		<link>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254</link>
		<comments>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254#comments</comments>
		<pubDate>Wed, 05 May 2010 20:57:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36254</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) started 2010 on a strong note with first quarter earnings beating expectations by a wide margin. The company reported first quarter earnings of $1.76 per share, 20 cents above the Zacks Consensus Estimate, and well above the year-ago earnings of $1.30. Top-line performance also remained strong with revenues increasing 14.7% to $596.6 million. The Quarter in Detail First quarter revenues consisted of $576.7 million in product sales (up 12%) and $19.9 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $307.1 million (up 14%) and $110 million (up 44%), respectively. Oncology drug Treanda continued to perform well, with sales coming in at $81.3 million, up 62%. Growing acceptance among hematologists should boost sales further ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/05/ceph-cephalons-quarterly-earnings-report-beats-updates-guidance/36254/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Earnings Estimates Up on Company Guidance</title>
		<link>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685</link>
		<comments>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685#comments</comments>
		<pubDate>Tue, 16 Mar 2010 22:00:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30685</guid>
		<description><![CDATA[Earnings estimates for Cephalon, Inc. (CEPH) have gone up significantly following the issuance of a better-than-expected guidance by the company. Cephalon exited 2009 on a strong note with both fourth-quarter and full-year earnings exceeding expectations. Cephalon reported fourth-quarter earnings of $1.66 per share, up 13.7%, and full-year earnings of $6.03, up 25%. Top-line performance also remained strong with fourth quarter revenues increasing 6.5% to $575.1 million, and full year revenues increasing 11% to $2.2 billion. Revenues were primarily driven by contributions from the central nervous system (CNS) and oncology franchises. Guidance and Earnings Estimate Revisions Cephalon’s guidance for 2010, which was re-issued following the company’s decision to acquire generic company Mepha, was well above expectations and resulted in several analysts raising their earnings estimates for the stock. Earnings estimates for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/16/ceph-cephalon-earnings-estimates-up-on-company-guidance/30685/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Beats Earnings Expectations and Guides Higher</title>
		<link>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882</link>
		<comments>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882#comments</comments>
		<pubDate>Fri, 12 Feb 2010 17:20:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27882</guid>
		<description><![CDATA[Cephalon, Inc. (CEPH) exited 2009 on a strong note with both fourth quarter and full year earnings exceeding expectations. The company reported fourth quarter earnings of $1.66 per share, 6 cents above the Zacks Consensus Estimate, and 13.7% above the year-ago earnings. Full year earnings came in at $6.03, easily surpassing the Zacks Consensus Estimate of $5.96 and the year-ago earnings of $4.82. Top-line performance also remained strong with fourth quarter revenues increasing 6.5% to $575.1 million, and full year revenues increasing 11% to $2.2 billion. Fourth Quarter Performance Fourth quarter revenues consisted of $562.9 million in product sales (up 5.2%) and $12.2 million in other revenues. Revenues were driven by contributions from the central nervous system (CNS) and oncology franchises, which posted sales of $302.4 million (up 1.6%) and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/12/ceph-cephalon-beats-earnings-expectations-and-guides-higher/27882/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CEPH) Cephalon Settles Barr Pharmaceuticals Challenge</title>
		<link>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374</link>
		<comments>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374#comments</comments>
		<pubDate>Thu, 26 Nov 2009 05:51:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21374</guid>
		<description><![CDATA[Earlier this month, Cephalon Inc. (CEPH) announced that it has settled its patent infringement case with Barr Pharmaceuticals, which is now owned by Teva Pharmaceutical (TEVA). Barr was looking to market a generic version of Cephalon’s cancer pain management drug, Fentora. As per the terms of the agreement, Barr has been granted a non-exclusive, royalty-free right to sell a generic version of Fentora in October 2018. However, if a generic version of Fentora enters the market prior to that date, Barr will be allowed to launch its generic version provided the other generic company does not enjoy marketing exclusivity. According to Cephalon, Fentora’s patent is not set to expire before 2019. While we are pleased to hear about this settlement agreement with Barr, we note that another major generic player, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/25/ceph-cephalon-settles-barr-pharmaceuticals-challenge/21374/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>($CEPH) Cephalon Beats Forecasts &#8211; Provides Outlook</title>
		<link>http://www.stockbloghub.com/2009/10/28/ceph-cephalon-beats-forecasts-provides-outlook/19067</link>
		<comments>http://www.stockbloghub.com/2009/10/28/ceph-cephalon-beats-forecasts-provides-outlook/19067#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:11:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BDSI]]></category>
		<category><![CDATA[BioDelivery Sciences International Inc]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19067</guid>
		<description><![CDATA[Cephalon Inc. (CEPH) reported strong third-quarter earnings of $1.62 per share that easily surpassed the Zacks Consensus Estimate of $1.42 per share and the year ago earnings of $1.18. Revenues increased 10.2% to $549 million, consisting of $535 million in product sales and $14.2 million in other revenues. Higher revenues and lower costs contributed to the robust results. Revenues were driven by contributions from the central nervous system [CNS] and oncology franchises, which posted sales of $291.9 million (up 7%) and $83.1 million (up 58%), respectively. Oncology drug Treanda continued to perform well, with sales coming in at $54.5 million. Additional data presentations on Treanda should help drive sales, especially in the indolent non-Hodgkin’s lymphoma (NHL) market. Cephalon reported $20.9 million in sales of its follow-on sleep franchise product, Nuvigil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/ceph-cephalon-beats-forecasts-provides-outlook/19067/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

